IP Library Granted Patent US 7,879,890
Granted Patent B2
US 7,879,890 · App. 12/338,445 · Granted Feb 1, 2011

Compounds for the treatment of inflammatory disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,879,890
App. No.
12/338,445
Granted
Feb 1, 2011
Kind
B2
Abstract

This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate, ester or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.

Claims (14)

1. A method of treating a condition or disease selected from the group consisting of septic shock, sepsis syndrome, post ischaemic reperfusion injury, meningitis, psoriasis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, inflammatory bowel disease, adults Still's disease, non-insulin dependent diabetes mellitus, asthma, and chronic obstructive pulmonary disease, wherein the method comprises: administering to a patient in need of such treatment a therapeutically effective amount of at least one compound selected from one of the following compounds:

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the compound is selected from the group consisting of

or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 , wherein the condition or disease is rheumatoid arthritis.

5. The method of claim 1 , wherein the condition or disease is inflammatory bowel disease.

6. The method of claim 5 , wherein the inflammatory bowel disease is Crohn's disease.

7. The method of claim 5 , wherein the inflammatory bowel disease is colitis.

8. The method of claim 1 , wherein the condition or disease is chronic obstructive pulmonary disorder.

9. The method of claim 1 , wherein the condition or disease is psoriasis.

10. The method of claim 1 , wherein the condition or disease is ankylosing spondylitis.

11. The method of claim 1 , wherein the condition or disease is psoriatic arthritis.

Assignments (2)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
CHANGE OF NAME Recorded Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →